| Financier | Commitments |
|---|---|
| International Bank for Reconstruction and Development | 35.00 |
AR: COVID-19 Emergency Response Project
Abstract*
Strategic and country context.
An outbreak of the coronavirus disease (COVID-19) caused by the 2019 novel coronavirus (SARS-CoV-2) has been spreading rapidly across the world since December 2019, following the diagnosis of the initial cases in Wuhan, Hubei Province, China. Since the beginning of March 2020, the number of cases outside China has increased thirteenfold and the number of affected countries has tripled. On March 11, 2020, the World Health... Show More
Development Objective
To strengthen preparedness and response efforts against the COVID-19 pandemic and national systems for public health preparedness in Argentina
Key Details
Project Details
P173767
Closed
Vanina Camporeale , Marvin Ploetz
Argentine Republic
March 19, 2020
(as of board presentation)
April 2, 2020
May 7, 2020
US$ 35.00 million
National Ministry of Health
2020
US$ 35.00 million
N/A
June 27, 2024
April 30, 2024
No
BANK APPROVED
Finances
Financing Plan (US$ Millions)
Total Project Financing (US$ Millions)
| Product Line | IBRD/IDA |
|---|---|
| IBRD Commitment | 35.00 |
| IDA Commitment | N/A |
| IBRD + IDA Commitment | 35.00 |
| Lending Instrument | |
|---|---|
| Grant Amount | N/A |
| Total Project Cost** | 35.00 |
Summary Status of World Bank Financing (US$ Millions) as of March 31, 2025
No data available.
| Period | Financier | Transaction Type | Amount (US$) |
|---|---|---|---|
| Oct 15, 2023 | IBRD-92920 | Int Charges | 262,844.34 |
| Oct 15, 2023 | IBRD-92920 | Int Charges | 2,506.98 |
| Oct 15, 2023 | IBRD-92920 | Int Charges | 5,915,254.00 |
| Nov 2, 2023 | IBRD-92920 | Loan Disb | 204,984.90 |
| Apr 2, 2020 | IBRD-90830 | Loan Commitment | 35,000,000.00 |
| Sep 30, 2021 | IBRD-92920 | Loan Commitment | 500,000,000.00 |
| Feb 16, 2024 | IBRD-92920 | Loan Disb | 628,098.20 |
| Apr 15, 2024 | IBRD-92920 | Int Charges | 10,938,280.00 |
| Apr 15, 2024 | IBRD-92920 | Int Charges | 172,732.44 |
| Apr 15, 2024 | IBRD-92920 | Int Charges | 2,136,342.00 |
| Apr 15, 2024 | IBRD-92920 | Int Charges | 1,362.10 |
| Apr 1, 2024 | IBRD-90830 | Int Charges | 18,300.50 |
| Apr 1, 2024 | IBRD-90830 | Int Charges | 1,280,529.60 |
| Apr 15, 2024 | IBRD-92920 | Int Charges | 777,604.50 |
| Nov 5, 2020 | IBRD-90830 | Loan Disb | 432,228.00 |
| Jun 12, 2020 | IBRD-90830 | Loan Disb | 351,864.22 |
| Jun 18, 2020 | IBRD-90830 | Loan Disb | 1,348,749.60 |
| Jun 29, 2020 | IBRD-90830 | Loan Disb | 4,357,082.00 |
| May 7, 2020 | IBRD-90830 | Loan Disb | 87,500.00 |
| May 7, 2020 | IBRD-90830 | Fee Charges | 87,500.00 |
| May 14, 2020 | IBRD-90830 | Loan Disb | 9,657,858.00 |
| Oct 1, 2020 | IBRD-90830 | Int Charges | 139,667.72 |
| Oct 30, 2020 | IBRD-90830 | Loan Disb | 121,500.00 |
| Dec 22, 2020 | IBRD-90830 | Loan Disb | 663,980.10 |
| Sep 4, 2020 | IBRD-90830 | Loan Disb | 97,879.06 |
| Oct 6, 2020 | IBRD-90830 | Loan Disb | 68,022.65 |
| Nov 17, 2020 | IBRD-90830 | Loan Disb | 479,242.00 |
| Oct 16, 2020 | IBRD-90830 | Loan Disb | 1,325,149.00 |
| Dec 17, 2020 | IBRD-90830 | Loan Disb | 288,237.60 |
| Oct 13, 2021 | IBRD-92920 | Loan Disb | 129,000,000.00 |
| Oct 15, 2021 | IBRD-92920 | Loan Disb | 172,000,000.00 |
| Oct 27, 2021 | IBRD-92920 | Loan Disb | 8,962,200.00 |
| Oct 6, 2021 | IBRD-92920 | Loan Disb | 1,250,000.00 |
| Oct 6, 2021 | IBRD-92920 | Fee Charges | 1,250,000.00 |
| Nov 15, 2021 | IBRD-92920 | Loan Disb | 11,501,100.00 |
| Nov 15, 2021 | IBRD-92920 | Loan Disb | 6,306,300.00 |
| Nov 9, 2021 | IBRD-92920 | Loan Disb | 32,502,600.00 |
| Nov 9, 2021 | IBRD-92920 | Loan Disb | 26,002,080.00 |
| Oct 1, 2021 | IBRD-90830 | Int Charges | 51.93 |
| Oct 1, 2021 | IBRD-90830 | Int Charges | 291,731.40 |
| Apr 1, 2021 | IBRD-90830 | Int Charges | 160.77 |
| Apr 1, 2021 | IBRD-90830 | Int Charges | 275,821.22 |
| Mar 23, 2021 | IBRD-90830 | Loan Disb | 27,303.19 |
| Feb 10, 2021 | IBRD-90830 | Loan Disb | -27,303.19 |
| Dec 21, 2021 | IBRD-92920 | Loan Disb | 32,139,900.00 |
| Dec 28, 2021 | IBRD-92920 | Loan Disb | 6,564,393.00 |
| Apr 1, 2022 | IBRD-90830 | Int Charges | 281,341.66 |
| Dec 22, 2021 | IBRD-92920 | Loan Disb | 13,334,507.00 |
| Dec 10, 2021 | IBRD-92920 | Loan Disb | 29,987,100.00 |
| Apr 15, 2022 | IBRD-92920 | Int Charges | 7,404.38 |
| Apr 15, 2022 | IBRD-92920 | Int Charges | 2,269,098.50 |
| Jul 9, 2020 | IBRD-90830 | Loan Disb | 4,055,998.00 |
| Oct 28, 2020 | IBRD-90830 | Loan Disb | 5,376,472.00 |
| Oct 22, 2020 | IBRD-90830 | Loan Disb | 6,000,000.00 |
| Nov 18, 2020 | IBRD-90830 | Loan Disb | 288,237.60 |
| Nov 16, 2021 | IBRD-92920 | Loan Disb | 3,247,920.00 |
| Nov 16, 2021 | IBRD-92920 | Loan Disb | 16,239,600.00 |
| Nov 1, 2021 | IBRD-92920 | Loan Disb | 8,962,200.00 |
| Apr 1, 2023 | IBRD-90830 | Int Charges | 45,618.98 |
| Apr 1, 2023 | IBRD-90830 | Int Charges | 961,841.80 |
| Apr 15, 2023 | IBRD-92920 | Int Charges | 509,331.88 |
| Apr 15, 2023 | IBRD-92920 | Int Charges | 219.19 |
| Apr 15, 2023 | IBRD-92920 | Int Charges | 1,659,284.10 |
| Apr 15, 2023 | IBRD-92920 | Int Charges | 3,920,000.00 |
| Apr 15, 2023 | IBRD-92920 | Int Charges | 10,901.03 |
| Apr 15, 2023 | IBRD-92920 | Int Charges | 84,489.75 |
| Apr 15, 2023 | IBRD-92920 | Int Charges | 5,155,526.50 |
| Apr 15, 2023 | IBRD-92920 | Int Charges | 139,496.34 |
| Apr 15, 2023 | IBRD-92920 | Int Charges | 1,581,400.10 |
| Apr 15, 2023 | IBRD-92920 | Int Charges | 2,781.55 |
| Apr 15, 2023 | IBRD-92920 | Int Charges | 219.19 |
| Oct 1, 2022 | IBRD-90830 | Int Charges | 558,752.20 |
| Oct 15, 2022 | IBRD-92920 | Int Charges | 7,104,858.00 |
| Jan 11, 2024 | IBRD-92920 | Loan Disb | 1,011,780.90 |
| Oct 1, 2023 | IBRD-90830 | Int Charges | 20,293.57 |
| Oct 1, 2023 | IBRD-90830 | Int Charges | 1,175,027.60 |
| Apr 15, 2024 | IBRD-92920 | Int Charges | 2,866,602.20 |
| Oct 15, 2023 | IBRD-92920 | Int Charges | 9,470,683.00 |
Ratings
IMPLEMENTATION RATINGS
| Name | Review | Date |
|---|---|---|
| Monitoring and Evaluation | Highly Satisfactory | 2024-07-19 |
| Overall Implementation Progress (IP) | Highly Satisfactory | 2024-07-19 |
| Procurement | Satisfactory | 2024-07-19 |
| Financial Management | Satisfactory | 2024-07-19 |
| Project Management | Satisfactory | 2024-07-19 |
| Progress towards achievement of PDO | Highly Satisfactory | 2024-07-19 |
| Financial Management | Satisfactory | 2024-07-19 |
| Monitoring and Evaluation | Satisfactory | 2024-07-19 |
| Overall Implementation Progress (IP) | Satisfactory | 2024-07-19 |
| Progress towards achievement of PDO | Highly Satisfactory | 2024-07-19 |
| Procurement | Satisfactory | 2024-07-19 |
| Project Management | Satisfactory | 2024-07-19 |
COMPLETION RATINGS
No data available.
INDEPENDENT EVALUATION RATINGS
No data available.
Results Framework
PROJECT DEVELOPMENT OBJECTIVE INDICATORS
| INDICATOR | BASELINE | CURRENT | TARGET |
|---|
Percentage of suspected cases of COVID-19 reported and investigated per approved protocols Value 0.00 96.00 90.00 Date February 28, 2020 May 31, 2022 December 29, 2023 Comment Percentage of diagnosed cases treated per approved protocols Value 0.00 100.00 90.00 Date February 28, 2020 May 31, 2022 December 29, 2023 Comment Percentage of acute healthcare facilities with increased isolation capacity Value 0.00 100.00 80.00 Date February 28, 2020 June 30, 2023 December 31, 2021 Comment Percentage of population vaccinated, which is included in the priority population targets, as defined in the NSVP for the Introduction of the Vaccine against COVID-19 (disaggregated by sex) Value 0.00 50.49 32.70 Date June 30, 2021 December 31, 2023 December 29, 2023 Comment Percentage of female population vaccinated, which is included in the priority population targets, as defined in the NSVP for the Introduction of the Vaccine against COVID-19 Value 0.00 53.13 32.70 Date June 30, 2021 December 31, 2023 December 29, 2023 Comment
INTERMEDIATE RESULTS INDICATORS
| INDICATOR | BASELINE | CURRENT | TARGET |
|---|
Number of laboratories conducting COVID-19 sample testing Value 1.00 35.00 24.00 Date February 28, 2020 June 30, 2023 December 29, 2023 Comment Percentage of public hospitals with Intensive Care Units strengthened Value 0.00 89.96 90.00 Date February 28, 2020 December 31, 2023 December 31, 2021 Comment Percentage of public hospitals with Intensive Care Units that received training according approved protocols Value 0.00 87.34 80.00 Date February 28, 2020 December 31, 2023 December 29, 2023 Comment Percentage of participating hospitals with personal protective equipment and infection control products and supplies, provided Value 0.00 89.08 90.00 Date February 28, 2020 June 30, 2023 December 31, 2021 Comment AR COVID-19 Fatality Rate Value 0.00 1.40 2.50 Date February 28, 2020 June 30, 2022 December 29, 2023 Comment Provincial Emergency Committees with multisectoral participation, including civil society organizations, created and operational” Value 0.00 70.83 70.00 Date March 19, 2020 December 31, 2023 December 29, 2023 Comment Number of doses of COVID-19 vaccine procured with Project funding Value 0.00 33397056.00 30000000.00 Date June 30, 2021 December 31, 2023 December 29, 2023 Comment Health staff trained in COVID-19 vaccination process according to protocols approved by the NMOH Value 5000.00 13560.00 10000.00 Date June 30, 2021 December 31, 2023 December 29, 2023 Comment Percentage of provinces with updated vaccination plans to implement the NSVP against COVID-19 Value 0.00 100.00 90.00 Date June 30, 2021 December 31, 2023 December 29, 2023 Comment Updated health management and information system to deploy a Pharmacovigilance strategy of AEFIs for COVID-19 vaccination with new guidelines according the NSVP and NMOH technical guidelines Value No Yes Yes Date June 30, 2021 December 31, 2023 December 29, 2023 Comment New Communication strategies developed and disseminated in support of the NSVP Value No Yes Yes Date June 30, 2021 December 31, 2023 December 29, 2023 Comment Share of women vaccinated against COVID-19 with at least one dose in the Northeastern region, in line with national average Value 51.00 85.60 59.00 Date August 3, 2021 December 31, 2023 December 29, 2023 Comment Share of women trained as vaccinators Value 50.00 79.00 60.00 Date June 30, 2021 December 31, 2023 December 29, 2023 Comment Share of female workers responsible for COVID-19 vaccination campaigns in Expanded Programs on Immunization (EPI) throughout the country Value 45.00 79.00 50.00 Date June 30, 2021 December 31, 2023 December 29, 2023 Comment Population fully vaccinated included in the priority population targets defined in the NSVP and NMOH technical guidelines (total and disaggregated by sex) Value 14.00 81.70 70.00 Date June 30, 2021 December 31, 2023 December 29, 2023 Comment